APO Research
Talk to an analyst

APO RESEARCH · REPORT

Migraine Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025195 pages

Choose your research edition.

Industry ResearchMigraine Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Migraine Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Migraine Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Migraine Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Migraine Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Migraine Drugs include Abbott, Johnson & Johnson, Merck, Eli Lilly, Pfizer, Pfizer, Bayer, Winston Pharmaceuticals and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Migraine Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Migraine Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Migraine Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Migraine Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Migraine Drugs Segment by Company

Abbott

Johnson & Johnson

Merck

Eli Lilly

Pfizer

Pfizer

Bayer

Winston Pharmaceuticals

Teva

Kowa Pharmaceuticals America

Impax

GlaxoSmithKline

Ethypharm

Endo International

AstraZeneca

Allergan

Migraine Drugs Segment by Type

Rizatriptan

Others Drug

Sumatriptan

Zolmitriptan

Migraine Drugs Segment by Application

Hospitals

Clinics

Household Use

Others

Migraine Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Migraine Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Migraine Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Migraine Drugs Industry Trends Table 2. Migraine Drugs Industry Drivers Table 3. Migraine Drugs Industry Opportunities and Challenges Table 4. Migraine Drugs Industry Restraints Table 5. Global Migraine Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Migraine Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Migraine Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Migraine Drugs Sales Market Share by Manufacturers Table 9. Global Migraine Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Migraine Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Migraine Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Migraine Drugs Manufacturers, Product Type & Application Table 13. Global Migraine Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Migraine Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rizatriptan Table 17. Major Manufacturers of Others Drug Table 18. Major Manufacturers of Sumatriptan Table 19. Major Manufacturers of Zolmitriptan Table 20. Global Migraine Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Migraine Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Migraine Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Migraine Drugs Sales Market Share by Type (2021-2026) Table 24. Global Migraine Drugs Sales Market Share by Type (2027-2032) Table 25. Global Migraine Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Migraine Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Migraine Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Migraine Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Migraine Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Household Use Table 33. Major Manufacturers of Others Table 34. Global Migraine Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Migraine Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global Migraine Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global Migraine Drugs Sales Market Share by Application (2021-2026) Table 38. Global Migraine Drugs Sales Market Share by Application (2027-2032) Table 39. Global Migraine Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Migraine Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global Migraine Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global Migraine Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Migraine Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Migraine Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Migraine Drugs Sales Market Share by Region (2021-2026) Table 47. Global Migraine Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Migraine Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America Migraine Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe Migraine Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Migraine Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Migraine Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Migraine Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Migraine Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Migraine Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Migraine Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Migraine Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Migraine Drugs Revenue Market Share by Region (2027-2032) Table 66. Abbott Company Information Table 67. Abbott Business Overview Table 68. Abbott Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Abbott Migraine Drugs Product Portfolio Table 70. Abbott Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Migraine Drugs Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Merck Migraine Drugs Product Portfolio Table 80. Merck Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eli Lilly Migraine Drugs Product Portfolio Table 85. Eli Lilly Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pfizer Migraine Drugs Product Portfolio Table 90. Pfizer Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pfizer Migraine Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. Bayer Company Information Table 97. Bayer Business Overview Table 98. Bayer Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Bayer Migraine Drugs Product Portfolio Table 100. Bayer Recent Development Table 101. Winston Pharmaceuticals Company Information Table 102. Winston Pharmaceuticals Business Overview Table 103. Winston Pharmaceuticals Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Winston Pharmaceuticals Migraine Drugs Product Portfolio Table 105. Winston Pharmaceuticals Recent Development Table 106. Teva Company Information Table 107. Teva Business Overview Table 108. Teva Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Teva Migraine Drugs Product Portfolio Table 110. Teva Recent Development Table 111. Kowa Pharmaceuticals America Company Information Table 112. Kowa Pharmaceuticals America Business Overview Table 113. Kowa Pharmaceuticals America Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Kowa Pharmaceuticals America Migraine Drugs Product Portfolio Table 115. Kowa Pharmaceuticals America Recent Development Table 116. Impax Company Information Table 117. Impax Business Overview Table 118. Impax Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Impax Migraine Drugs Product Portfolio Table 120. Impax Recent Development Table 121. GlaxoSmithKline Company Information Table 122. GlaxoSmithKline Business Overview Table 123. GlaxoSmithKline Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. GlaxoSmithKline Migraine Drugs Product Portfolio Table 125. GlaxoSmithKline Recent Development Table 126. Ethypharm Company Information Table 127. Ethypharm Business Overview Table 128. Ethypharm Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Ethypharm Migraine Drugs Product Portfolio Table 130. Ethypharm Recent Development Table 131. Endo International Company Information Table 132. Endo International Business Overview Table 133. Endo International Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Endo International Migraine Drugs Product Portfolio Table 135. Endo International Recent Development Table 136. AstraZeneca Company Information Table 137. AstraZeneca Business Overview Table 138. AstraZeneca Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. AstraZeneca Migraine Drugs Product Portfolio Table 140. AstraZeneca Recent Development Table 141. Allergan Company Information Table 142. Allergan Business Overview Table 143. Allergan Migraine Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Allergan Migraine Drugs Product Portfolio Table 145. Allergan Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Migraine Drugs Distributors List Table 149. Migraine Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Migraine Drugs Product Image Figure 2. Global Migraine Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Migraine Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Migraine Drugs Sales (2021-2032) & (K Units) Figure 5. Global Migraine Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Migraine Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rizatriptan Image Figure 9. Others Drug Image Figure 10. Sumatriptan Image Figure 11. Zolmitriptan Image Figure 12. Global Migraine Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Migraine Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Migraine Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Migraine Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Migraine Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Migraine Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Household Use Image Figure 21. Others Image Figure 22. Global Migraine Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Migraine Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Migraine Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Migraine Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Migraine Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Migraine Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Migraine Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Migraine Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Migraine Drugs Sales Market Share by Country (2021-2032) Figure 42. China Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Migraine Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Migraine Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Migraine Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Migraine Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Migraine Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Migraine Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Migraine Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Migraine Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Migraine Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Migraine Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Rizatriptan
  • Others Drug
  • Sumatriptan
  • Zolmitriptan
Applications
  • Hospitals
  • Clinics
  • Household Use
  • Others
Companies covered
  • Abbott
  • Johnson & Johnson
  • Merck
  • Eli Lilly
  • Pfizer
  • Pfizer
  • Bayer
  • Winston Pharmaceuticals
  • Teva
  • Kowa Pharmaceuticals America
  • Impax
  • GlaxoSmithKline
  • Ethypharm
  • Endo International
  • AstraZeneca
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Migraine Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Migraine Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Migraine Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Migraine Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Migraine Drugs Market Dynamics
  1. 2.1 Migraine Drugs Industry Trends
  2. 2.2 Migraine Drugs Industry Drivers
  3. 2.3 Migraine Drugs Industry Opportunities and Challenges
  4. 2.4 Migraine Drugs Industry Restraints
3 Migraine Drugs Market by Manufacturers
  1. 3.1 Global Migraine Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Migraine Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Migraine Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Migraine Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Migraine Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Migraine Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Migraine Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Migraine Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Migraine Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Migraine Drugs Market by Type
  1. 4.1 Migraine Drugs Type Introduction
  2. 4.1.1 Rizatriptan
  3. 4.1.2 Others Drug
  4. 4.1.3 Sumatriptan
  5. 4.1.4 Zolmitriptan
  6. 4.2 Global Migraine Drugs Sales by Type
  7. 4.2.1 Global Migraine Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Migraine Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Migraine Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Migraine Drugs Revenue by Type
  11. 4.3.1 Global Migraine Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Migraine Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Migraine Drugs Revenue Market Share by Type (2021-2032)
5 Migraine Drugs Market by Application
  1. 5.1 Migraine Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Household Use
  5. 5.1.4 Others
  6. 5.2 Global Migraine Drugs Sales by Application
  7. 5.2.1 Global Migraine Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Migraine Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Migraine Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Migraine Drugs Revenue by Application
  11. 5.3.1 Global Migraine Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Migraine Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Migraine Drugs Revenue Market Share by Application (2021-2032)
6 Global Migraine Drugs Sales by Region
  1. 6.1 Global Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Migraine Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Migraine Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Migraine Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Migraine Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Migraine Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Migraine Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Migraine Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Migraine Drugs Revenue by Region
  1. 7.1 Global Migraine Drugs Revenue by Region
  2. 7.1.1 Global Migraine Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Migraine Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Migraine Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Migraine Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Migraine Drugs Revenue (2021-2032)
  8. 7.2.2 North America Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Migraine Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Migraine Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Migraine Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Migraine Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Migraine Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Migraine Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Migraine Drugs Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Migraine Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Migraine Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Migraine Drugs Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 Winston Pharmaceuticals
  44. 8.8.1 Winston Pharmaceuticals Company Information
  45. 8.8.2 Winston Pharmaceuticals Business Overview
  46. 8.8.3 Winston Pharmaceuticals Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Winston Pharmaceuticals Migraine Drugs Product Portfolio
  48. 8.8.5 Winston Pharmaceuticals Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Migraine Drugs Product Portfolio
  54. 8.9.5 Teva Recent Developments
  55. 8.10 Kowa Pharmaceuticals America
  56. 8.10.1 Kowa Pharmaceuticals America Company Information
  57. 8.10.2 Kowa Pharmaceuticals America Business Overview
  58. 8.10.3 Kowa Pharmaceuticals America Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kowa Pharmaceuticals America Migraine Drugs Product Portfolio
  60. 8.10.5 Kowa Pharmaceuticals America Recent Developments
  61. 8.11 Impax
  62. 8.11.1 Impax Company Information
  63. 8.11.2 Impax Business Overview
  64. 8.11.3 Impax Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Impax Migraine Drugs Product Portfolio
  66. 8.11.5 Impax Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Migraine Drugs Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Ethypharm
  74. 8.13.1 Ethypharm Company Information
  75. 8.13.2 Ethypharm Business Overview
  76. 8.13.3 Ethypharm Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ethypharm Migraine Drugs Product Portfolio
  78. 8.13.5 Ethypharm Recent Developments
  79. 8.14 Endo International
  80. 8.14.1 Endo International Company Information
  81. 8.14.2 Endo International Business Overview
  82. 8.14.3 Endo International Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Endo International Migraine Drugs Product Portfolio
  84. 8.14.5 Endo International Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Migraine Drugs Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Allergan
  92. 8.16.1 Allergan Company Information
  93. 8.16.2 Allergan Business Overview
  94. 8.16.3 Allergan Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Allergan Migraine Drugs Product Portfolio
  96. 8.16.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Migraine Drugs Value Chain Analysis
  2. 9.1.1 Migraine Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Migraine Drugs Production Mode & Process
  6. 9.2 Migraine Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Migraine Drugs Distributors
  9. 9.2.3 Migraine Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst